P209 Syndrome lipodystrophique par mutation de PPAR gamma

Vantyghem, Marie-Christine; Duvivier, E; Pascal, Mariona; Sterkers, Adrien; Lascols, Olivier; Wémeau, J. L.; Maurage, C.A.

doi:10.1016/s1262-3636(10)70357-8

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25) It is important to maintain PPARγ expression and activity for energy metabolism and insulin resistance; however, excessive PPARγ activity could result in obesity and lipodystrophy. [26][27][28] In obesity, PPARγ is highly expressed in adipose tissues, and it induces specific adipogenic genes for adipocyte differentiation. Differentiation from preadipocytes to mature adipocytes is a critical step in determining obesity progression.…”

Section: Discussionmentioning

confidence: 99%

Dlx5 Represses the Transcriptional Activity of PPARγ

Kim

Cho

Chung

et al. 2021

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Peroxisome proliferator-activated receptor gamma (PPARγ) is a master transcription factor in adipocyte differentiation, while distal-less homeobox 5 (Dlx5) is essential for initiating osteoblast differentiation by driving Runt-related transcription factor 2 expression. Considering that adipocytes and osteoblasts share common progenitors, there is a reciprocal correlation between bone and fat formation. However, the mechanism by which Dlx5 controls PPARγ remains unclear. We elucidated that Dlx5 physically binds to PPARγ during immunoprecipitation; in particular, the ligand-binding and DNA-binding domains of PPARγ were involved in the interaction. Transcriptional activity of PPARγ was significantly decreased by Dlx5 overexpression, whereas the opposite results were detected with Dlx5 knockdown. Rosiglitazone, a PPARγ agonist, further enhanced the PPARγ-induced transcriptional activity; however, Dlx5 overexpression effectively repressed the rosiglitazone-mediated increase in activity. Finally, DNA-binding affinity assay revealed that Dlx5 interrupts the interaction of PPARγ with the PPARγ response element promoter. In conclusion, our findings indicate that Dlx5 impedes PPARγ-induced activity, and it may be useful for managing diabetes drugmediated obesity.

show abstract